

Five-Year Summary

€ million	2018	2019	2020	2021	2022
Bayer Group financial KPIs					
Sales	36,742	43,545	41,400	44,081	50,739
EBITDA ¹	9,695	9,529	(2,910)	6,409	13,515
EBITDA before special items ¹	8,969	11,474	11,461	11,179	13,513
EBITDA margin before special items ¹	24.4%	26.3%	27.7%	25.4%	26.6%
EBIT ¹	3,454	4,162	(16,169)	3,353	7,012
EBIT before special items ¹	6,013	6,975	7,095	7,295	9,257
Income before income taxes	1,886	2,853	(17,250)	2,046	4,670
Net income (from continuing and discontinued operations)	1,695	4,091	(10,495)	1,000	4,150
Earnings per share (from continuing and discontinued operations) (€) ¹	1.80	4.17	(10.68)	1.02	4.22
Core earnings per share (from continuing operations) (€) ¹	5.60	6.38	6.39	6.51	7.94
Free cash flow	4,652	4,214	1,343	1,415	3,111
Net financial debt	35,679	34,068	30,045	33,137	31,809
Capital expenditures (newly capitalized)	2,368	2,920	3,138	3,004	3,639
Return on capital employed (ROCE) (%)	4.0	3.7	-16.5	3.8	7.7
Bayer AG					
Total dividend payment	2,611	2,751	1,965	1,965	2,358
Dividend per share (€)	2.80	2.80	2.00	2.00	2.40
Bayer Group nonfinancial KPIs²					
Number of smallholder farmers in low- and middle-income countries supported by products, services and partnerships (million)	42	45	49	52	
Number of women in low- and middle-income countries who have their need for modern contraception satisfied due to interventions supported by Bayer (million)	38	40	41	44	
Number of people in underserved ³ communities whose self-care is supported by interventions from Bayer (million)	41	43	46	49	
Scope 1 and 2 greenhouse gas emissions (million metric tons)	3.76	3.58	3.17	3.03	
Scope 3 greenhouse gas emissions from relevant categories (million metric tons)	8.82	8.22	7.91	8.90	
Off-setting of remaining Scope 1 and 2 greenhouse gas emissions in 2030 (million metric tons)	0.00	0.20	0.30	0.45	
Innovation					
Research and development expenses ⁴	5,105	5,301	7,126	5,412	6,572
Ratio of R&D expenses to sales – Crop Science (%) ⁵	13.0	11.3	10.4	10.5	10.1
Ratio of R&D expenses to sales – Pharmaceuticals (%) ⁵	15.5	15.6	15.5	16.1	17.3
Ratio of R&D expenses to sales – Consumer Health (%) ⁵	4.1	3.9	3.8	3.7	3.6
Employees					
Number of employees ⁶ (Dec. 31)	107,894	103,824	99,538	99,637	101,369
Personnel expenses (including pension expenses) (€ million)	10,778	11,788	9,769	11,798	12,619
Safety & environmental protection					
Recordable Incident Rate (RIR) for Bayer employees	0.40	0.46	0.32	0.38	0.37
Process Safety Incident Rate (PSI-R)	–	0.10	0.08	0.08	0.11
Total energy consumption (petajoules)	28.9	39.2	35.9	34.8	35.5
Energy efficiency (kWh/€1,000) ⁷	219	250	241	220	194
Hazardous waste generated (thousand metric tons)	303	316	305	316	276
Water use (million m ³)	42	59	57	55	53

2021 figures restated; figures for 2018 – 2020 as last reported

¹ For definition see A 2.3 “Alternative Performance Measures Used by the Bayer Group.”

² For more information see A 1.2.1.

³ Economically or medically

⁴ The increase in R&D expenses in 2020 was mainly due to special charges in connection with impairment charges at Crop Science.

⁵ R&D expenses before special items

⁶ Employees calculated as full-time equivalents (FTEs)

⁷ Quotient of total energy consumption and external sales